Biotech Business - August 19, 2026
BioArctic and Mesenkia enter research collaboration
BioArctic and Mesenkia Therapeutics have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.
Collaboration - August 19, 2026
New Nordic centre aims to strengthen glymphatic system research
The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.
Collaboration - August 19, 2026
Navinci and BrainZell initiate collaboration
Navinci Diagnostics has initiated a collaboration with BrainZell to explore the use of Navinci’s in situ Proximity Ligation Assay technology in human brain organoid models to support relevant studies of biology and drug response.
In a new job - August 18, 2026
He is the new President and CEO of BICO Group AB
The Board of Directors of BICO Group AB has announced the appointment of Anders Fogelberg, currently Chief Commercial Officer, as President and CEO, effective September 1, 2026.
Pharma Business - August 18, 2026
Hansa Biopharma announces first commercial kidney transplant patient treated with Idefirix in Australia
Hansa Biopharma has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).
Acquisition - August 18, 2026
LEO Pharma acquires dersimelagon rights from Tanabe
LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.
